Greenwich LifeSciences, Inc.
GLSINASDAQ
Healthcare
$22.70
-0.26(-1.13%)
Mkt Cap $314M
$7.85
$33.57
52-Week Range
At A Glance
1
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
2
No significant events in the past 90 days.
$314M
Market Cap
—
Revenue
-$20M
Net Income
Employees4
Fundamentals
How The Business Makes Money
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIK0001799788
ISINUS3968791083
CUSIP396879108
Phone832 819 3232
AddressBuilding 14, Stafford, TX, 77477, US
SEC EDGAR